GH Research Is Taking its Psychedelic 5-MeO-DMT 'Toad Venom' Public

GH Research Is Taking Psychedelic 5-MeO-DMT ‘Toad Venom’ Public

GH Research is taking its psychedelic 5-MeO-DMT public on the Nasdaq with an IPO valued at more than $100 million.
AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 Million

AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 Million

Nue Life Health is a new therapy platform relying on AI and music as well as psychedelics for customized healing.
Biotech Firm PsyBio Therapeutics Is Producing Psilocybin From Bacteria

Biotech Firm PsyBio Therapeutics Is Producing Psilocybin From Bacteria

PsyBio Therapeutics is harvesting the psychedelic compound psilocybin from a strain of bacteria instead of mushrooms.
Psychedelic Business News Spotlight

Psychedelic Business Spotlight: June 4, 2021

,
This week in psychedelic business: Mindset Pharma's new research, synthetic ibogaine, and the Western Hemisphere gets its first “smart shop.”

How Do our Genes Affect an LSD TRIP?? New MindMed Study [ MMED / MNMD ]

Does our Genetic makeup influence our LSD trip? Hey psychedelic Investors! MindMed ( MMED/MNMD/MMQ ) recently published a study in Nature Scientific Reports examining the different variations in our genes and how they affect one's experience during an LSD trip. The results are leading us to infer that, soon, we might be able to predict the strength, duration and perhaps even the subjective experience one undergoes when taking LSD based on certain genes that we possesses. If we're able to do that, how will this affect LSD’s medical uses in therapy setting? Can we use this knowledge to move towards personalized dosing, where each individual will receive a different dose level for the same procedure, based on what their genetic code tells the therapist? We will answer these questions in today's episode . We will also take a deep dive into the LSD study itself and explain why the findings are important for the future of psychedelic-assisted psychotherapy. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor editing: @themyaholy Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedNews #MindMedstock
New York Bill Proposes State-Sponsored Psychedelic Research Institute

New York Bill Proposes State-Sponsored Psychedelic Research Institute

New York is looking to explore psychedelic research through the formation of a new institute to investigate the healing potential.

HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)

HAVN VS. Mindmed - Whose Cluster Headache Treatment Is Better? Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our "This Week In Psychedelic Stocks" segment. In light of HAVN's recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore. HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind. Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020. The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms. DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. Full Disclosure: This video is for entertainment only and shouldn't be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) . https://havnlife.com/ CSE: HAVN | OTC: HAVLF | FRA: 5NP #HAVN #HAVNLifeSciences #Mindmed
California Senate Passes Psychedelic Decriminalization Bill

California Senate Passes Psychedelic Decriminalization Bill

California is poised to become the second U.S. state to decriminalize possession and use of psychedelics following Oregon.
How to Become a Psychedelic Facilitator

How a Psilocybin Retreat Changed Everything I Knew About Psychedelics

,
Here's how a legal psilocybin truffle retreat in the Netherlands changed this author's relationship with psychedelics.

BIPOC Medicine Healing with the Ancestor Project

Charlotte James and "Dre” Wright of The Ancestor Project chat with our Director of Content, Jill Ettinger.